Kala Pharmaceuticals, Inc. (KALA) earnings
KALA earnings moved a median of -1.01% by the close. Quarterly and annual KALA reports and results, each read against the price at its own news timestamp. Back to the KALA overview →
21 measured KALA earnings events.
Where these KALA earnings landedvs 21 measured KALA earnings reactions
| Middle 50% of KALA earnings reactions | -2.92% to +0.69% |
|---|---|
| Median reaction (to close) | -1.01% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 KALA earnings events with a measured close landed between -2.92% and +0.69%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q KALA BIO, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -10.53% | |
| Form NT 10-Q KALA BIO, Inc. For: Jun 30 | SEC filing · Form NT | -3.33% | +3.01% | |
| Form 10-Q KALA BIO, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.17% | -1.01% | |
| Form 10-K KALA BIO, Inc. For: Dec 31 | SEC filing · Form 10-K | -4.13% | -3.87% | |
| Form NT 10-K KALA BIO, Inc. For: Dec 31 | SEC filing · Form NT | +8.33% | -9.44% | |
| Form 10-Q KALA BIO, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.01% | -8.26% | |
| Form NT 10-Q KALA BIO, Inc. For: Sep 30 | SEC filing · Form NT | -2.78% | -2.92% | |
| Form 10-Q KALA BIO, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.98% | +3.65% | |
| KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.98% | +3.65% | |
| Form 10-Q KALA BIO, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -1.23% | |
| KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.89% | -3.25% | |
| Form 10-K KALA BIO, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.78% | -2.55% | |
| Form 10-Q KALA BIO, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.05% | -0.71% | |
| KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.97% | -2.88% | |
| Form 10-Q KALA BIO, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.77% | -1.13% | |
| KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.68% | +4.03% | |
| Form 10-Q KALA BIO, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.69% | |
| KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | +0.69% | |
| Form 10-K KALA BIO, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.13% | |
| Form 10-Q KALA BIO, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.55% | +0.62% | |
| KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +0.55% | +0.62% |
Keep exploring
More KALA: analyst actions → · SEC filings → · KALA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cytosorbents Corporation (CTSO) | 249 | 0.00% | 49% |
| IRIDEX Corporation (IRIX) | 248 | +0.11% | 52% |
| MELINTA THERAPEUTICS INC (MLNT) | 248 | -0.38% | 34% |
| Heron Therapeutics, Inc. (HRTX) | 247 | -0.34% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.